Table 2.
Patients’ characteristics according to clinical stage.
| Variable | Early Stage | Advanced Stage | p-Value |
|---|---|---|---|
| N (%) | N (%) | ||
| 513 | 1448 | ||
| Gender | 0.078 | ||
| Female | 233 (45%) | 593 (41%) | |
| Male | 280 (55%) | 855 (59%) | |
| Age at molecular diagnosis | 0.023 | ||
| Median (min–max) | 70 (27–86) | 68 (23–90) | |
| EGFR | 70/513 (13.6%) | 200/1448 (13.8%) | 0.925 |
| ALK | 25/513 (4.8%) | 82/1438 (5.7%) | 0.479 |
| ROS1 | 2/513 (0.39%) | 7/1443 (0.48%) | 0.784 |
| BRAF | 18/513 (3.5%) | 53/1448 (3.6%) | 0.543 |
| V600E | 10 (1.9%) | 37 (2.5%) | |
| Other variant | 8 (1.5%) | 16 (1.1%) | |
| KRAS | 159/513 (30.9%) | 377/1448 (26%) | 0.045 |
| G12C | 53/513 (10.3%) | 146/1448 (10.1%) | |
| Other variant | 106/513 (20.6%) | 231/1448 (15.9%) | |
| MET exon 14 skipping | 3/58 (5.2%) | 10/149 (6.7%) | 0.682 |
| RET | 2/58 (3.4%) | 5/149 (3.3%) | 0.974 |
| TP53 | 107/455 (23.5%) | 347/1304 (26.6%) | 0.194 |
| PIK3CA | 16/513 (3.1%) | 59/1448 (4.1%) | 0.332 |
| ERBB2 | 4/513 (0.8%) | 13/1448 (0.9%) | 1.000 |
| PD-L1 | |||
| score 0 (<1%) | 163/357(45.7%) | 405/994 (40.7%) | 0.104 |
| score 1 (1–49%) | 135/357 (37.8%) | 377/994 (37.9%) | |
| score 2 (≥50%) | 59/357 (16.5%) | 212/994 (21.4%) |